Rsc Pharmaceutics
Overview
Rsc Pharmaceutics is a scientific journal, published by Royal Society of Chemistry since 2024 in English. The journal's country of origin is United Kingdom.
Details
Details
Abbr.
RSC Pharm
Publisher
Royal Society of Chemistry
Start
2024
End
Continuing
Frequency
Bimonthly
e-ISSN
2976-8713
Country
United Kingdom
Language
English
Recent Articles
1.
Sterin E, Weinstein L, Roy Chowdhury C, Guzzetti E, Day E
RSC Pharm
. 2025 Mar;
PMID: 40083440
Tracking nanoparticles' location is imperative for understanding cellular interactions, pharmacokinetics, and biodistribution. DiD is a lipophilic dye commonly used to label nanoparticles for trafficking studies. Herein, we show that DiD...
2.
Wagner A, Lanier O, Savk A, Peppas N
RSC Pharm
. 2025 Feb;
PMID: 39990011
Ovarian cancer is one of the leading causes of cancer-related deaths in women, with limited progress in treatments despite decades of research. Common treatment protocols rely on surgical removal of...
3.
Eixenberger J, Anders C, Hermann R, Wada K, Reddy K, Montenegro-Brown R, et al.
RSC Pharm
. 2024 Dec;
2(1):82-93.
PMID: 39703205
Nanomedicines offer high promise for the treatment of various diseases, and numerous novel approaches using nanomaterials have been developed over the years. In this report, we introduce a new strategy...
4.
Shaw J, Vaidya R, Xu F, Dharmaraj S, Pearson R
RSC Pharm
. 2024 Dec;
2(1):135-146.
PMID: 39650739
Polymeric nanoparticles (NPs) are traditionally formulated using batch methodologies that are poorly scalable and require time consuming, hands-on purification procedures. Here, we prepared poly(lactic acid) (PLA)-based polymeric NPs using a...
5.
Ehrenzeller S, Lukesh N, Stiepel R, Middleton D, Nuzzolo S, Tate A, et al.
RSC Pharm
. 2024 Oct;
1(4):727-741.
PMID: 39415944
Rapamycin (rapa), an immunosuppressive medication, has demonstrated considerable effectiveness in reducing organ transplant rejection and treating select autoimmune diseases. However, the standard oral administration of rapa results in poor bioavailability,...
6.
Ranjan A, Czyzyk D, Martinez-Traverso G, Sadiqova A, Valhondo M, Schaefer D, et al.
RSC Pharm
. 2024 Oct;
1(5):963-975.
PMID: 39372445
The gastrointestinal disease cryptosporidiosis, caused by the genus , is a common cause of diarrheal diseases in children, particularly in developing countries and frequently fatal in immunocompromised individuals. ()-specific bifunctional...
7.
McMillan C, Druschitz A, Rumbelow S, Borah A, Binici B, Rattray Z, et al.
RSC Pharm
. 2024 Sep;
1(4):841-853.
PMID: 39323767
Lipid nanoparticles (LNPs), most commonly recognised for their role in COVID-19 mRNA vaccines, are important delivery vehicles for nucleic acid (mRNA, siRNA) therapies. The physicochemical attributes, such as size, nucleic...
8.
Dauda A, Swift T, Telford R, El-Wahab H, Danta C, Pors K, et al.
RSC Pharm
. 2024 Jun;
1(2):272-282.
PMID: 38899150
Mitonafide-loaded liposomes are a promising strategy to overcome the neurotoxicity observed in clinical trials for this drug. This study investigates the influence of loaded mitonafide or a dimer analogue on...
9.
Zou H, Boboltz A, Cheema Y, Song D, Cahn D, Duncan G
RSC Pharm
. 2024 Jun;
1(2):218-226.
PMID: 38899149
A mucus gel layer lines the luminal surface of tissues throughout the body to protect them from infectious agents and particulates. As a result, nanoparticle drug delivery systems delivered to...
10.
Varache M, Rizzo S, Sayers E, Newbury L, Mason A, Liao C, et al.
RSC Pharm
. 2024 Apr;
1(1):68-79.
PMID: 38646595
The acute kidney injury (AKI) and dose-limiting nephrotoxicity, which occurs in 20-60% of patients following systemic administration of colistin, represents a challenge in the effective treatment of multi-drug resistant Gram-negative...